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ABSTRACT 
Developing a Clinical Tool for the Assessment and Diagnosis of Pediatric Bipolar 
Disorder 
Background: Pediatric bipolar disorder is a significant mental illness, 
characterized by changes in mood that can be abrupt, unpredictable, and extreme.  The 
rate of diagnosis of this disorder has been increasing in recent decades.  Purpose: A 
thorough review of existing literature was completed to inform practice.  Additionally, a 
survey of clinician assessment practices was completed.  Combining the information 
learned from the literature review, and the data from the clinician survey, a clinical tool 
has been created.  This tool provides a thorough, multi-phasic process for the assessment 
and diagnosis of pediatric bipolar disorder.  Method: Mental health clinicians were 
surveyed; respondents were obtained via snowball sampling.  Chi square analysis was 
completed to determine the relationships between the assessment practices used and the 
level of licensure of the clinician, the length of time the clinician had been in practice, 
and the age range treated by the clinician.  Results: No statistically significant results 
were identified from the Chi Square analyses.  Inconsistency in the assessment strategies 
was noted, however.  Implications/Conclusions: Further clinician data should be 
obtained due to the small sample size (n=16).  The resulting tool has been reviewed by a 
subject matter expert and will be validated in practice before diffusion.    
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CHAPTER 1: INTRODUCTION 
Background 
Bipolar disorder (BPD) is a serious mental health condition characterized by 
recurrent periods of depression and elevated mood; these mood shifts are accompanied by 
cognitive and behavioral symptoms (Anderson, Haddad, & Scott, 2012).  Dilsaver (2011) 
reported an estimated lifetime incidence of bipolar spectrum disorders is between 4.4% 
and 6.4%.  Pediatric BPD is becoming more prevalent in the United States (US); in 1996 
BPD was the least common diagnosis for children receiving inpatient psychiatric care, 
and by 2004 it was the most common (Littrell and Lyons, 2010).  Contributing factors to 
this rise in diagnosis include an expansion of criteria to include a spectrum of BPD’s, and 
a greater understanding of the genetic heritability of the condition (Littrell & Lyons, 
2010). The incidence rate of BPD in the pediatric population is approximately 2% 
(Youngstrom, Jenkins, Jensen-Doss, & Youngstrom, 2012).   
Across the lifespan, the implications of BPD are more significant than the other 
disorders that have similar clinical presentations, like attention deficit hyperactivity 
disorder (ADHD) or oppositional defiant disorder (ODD).  Goldstein (2009) reported a 
lifetime rate of suicidal ideation of up to 75%, a 44% suicide attempt rate, and a 
completed suicide rate of 25% for those with BPD.  BPD is also known to be a kindling 
illness, making an accurate diagnosis and early treatment important (Weiss et al., 2015).  
Kindling refers to the phenomenon whereby the experience of life stress causes mood 
cycles to exacerbate in individuals suffering from conditions like BPD (Weiss, et al., 
2015). 
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Purpose 
 The purpose of this project was to complete a thorough review of existing 
literature about pediatric BPD, to conduct a survey amongst mental health clinicians, and 
use the information and data obtained from these processes, to create a clinical tool for 
the assessment and diagnosis of pediatric BPD.  Literature has been reviewed to provide 
an evidence-based foundation for the development of the tool.  Clinicians were queried 
and their responses analyzed to determine the level of licensure, the length of time in 
practice, age ranges treated, and assessment strategies employed.  Research questions 
analyzed were: 
1) Is there a significant difference between the type of licensure that a clinician holds 
and the assessment strategies used in clinical practice? 
2) Is there a significant difference between the length of time a clinician has been in 
practice and the assessment strategies used in clinical practice? 
3) Is there a difference between the age ranges that clinicians treat and the 
assessment strategies used in clinical practice? 
Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) proposed several 
evidence-based steps that could be followed to assess pediatric BPD, but failed to 
incorporate a tool that could be used or medical screening elements.  This project created 
a process that will incorporate clinical interviewing, obtaining collateral data, completing 
valid and reliable screening tools, and obtaining diagnostic studies before assigning this 
diagnosis.  It is expected that the robust nature of the screening tool will allow for rapid 
adoption of the process by clinicians (Dearing, 2009).    
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Current assessment practices to diagnose pediatric BPD are often subjective, 
inconsistent, and do not follow a cohesive, researched process (Jenkins, Youngstrom, 
Youngstrom, Feeny, & Findling, 2011).  Additionally, these authors noted that BPD, 
compared to other conditions, is more challenging to accurately diagnose due to the 
varying mood states in which a patient may present (Jenkins et al., 2011).  A patient with 
Bipolar I disorder, for example, may present for treatment in full mania, hypomania, 
euthymia, dysthymia, severe depression, or a mixed state.  Clinicians should conduct 
thorough interviews, and incorporate valid screening tools to assist in making a BPD 
diagnosis.  It is also important to incorporate evidence-based, objective methods of 
assessment to reduce diagnostic ambiguity.  Accurate, early identification and treatment 
will yield more positive patient outcomes due to the initiation of earlier treatment 
(Maniscalco & Hamrin, 2008).   
It is thought that in some situations pediatric BPD is over diagnosed, and in other 
scenarios, it is misdiagnosed as another condition (Danner et al., 2009).  Several pediatric 
mental health conditions have overlapping symptoms (Youngstrom, Birmaher, & 
Findling, 2008), and consequently, this makes accurate diagnosis challenging.  
Youngstrom et al. noted that irritable mood, distractibility, and pressured speech are 
common in pediatric BPD, but that these symptoms are not sensitive to the condition.   
Conduct disorder (CD), ODD, and ADHD all share symptoms in common with pediatric 
BPD, and they can be mistaken for each other clinically (Danner, et al., 2009).   
Post et al., (2015) noted that there is a life expectancy loss of 13-30 years in 
individuals who have a serious mental illness.  BPD is considered serious mental illness, 
according to DeHert et al., (2011).  BPD is a costly public health issue, Dilsaver (2011) 
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noted that the economic burden of bipolar I and bipolar II disorders is 151 billion dollars 
in the US annually.  The significance of these statistics provides support for the diffusion 
of the clinical tool as an innovative clinical process.  The degree to which the tool can 
help to change these statistics should be highlighted to increase the likelihood of adoption 
by clinicians.  The tool represents an innovation to enhance current assessment strategies, 
and the diffusion of the attributes of the tool will aid clinicians in adopting the new 
process (Dearing, 2009). 
Theoretical Framework 
 Diffusion of innovation theory provides a foundation and guide for the execution 
of this project.  This theory involves taking the innovative idea of the clinical tool, and 
diffusing its content and use to clinicians, the clinicians choosing to accept the innovative 
process, and clinicians adopting the innovation into practice (Dearing, 2009).  The 
beneficial attributes of the process must be readily identified by clinicians to aid in their 
ease of adoption.  Information regarding the evidence-based assessment strategies 
incorporated, and rationale behind the recommendations for the innovative aspects of the 
tool will have to be diffused to clinicians to aid in their adoption process (Dearing, 2009).   
The theory suggests that accelerated diffusion of concepts, and thus accelerated adoption 
of the innovation can be achieved by incorporating validated concepts (Dearing, 2009).  
The clinical tool has achieved this by clustering together several evidence-based 
assessment strategies for the first several phases of assessment.   
Murray (2009) discussed the application of the diffusion of innovation theory to 
psychotherapy practice.  Murray reviewed the major tenets of the theory, and ultimately 
discussed that clinicians will more readily adopt the innovation into practice if they find 
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the research meaningful to their clinical work (Murray, 2009).  The clinical tool was 
developed with this in mind.  Training and dissemination efforts will need to focus on 
ensuring clinicians can recognize the value of the new process, as well as its ease of use 
and adoption clinically. 
 
   
CHAPTER 2: LITERATURE REVIEW 
Assessment and Diagnosis 
 Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) reviewed evidence-
based assessment strategies used to diagnose pediatric BPD.  The authors provided an 
algorithm of steps that could be used to assess for this condition, as well as a figure 
diagramming the use of these steps.  There was no tool or manner in which the presented 
process should be applied in the clinical setting.  Some similarities include the inclusion 
of several commonly utilized evidence-based assessment strategies.  Some of the 
differences include that the authors of the article provided some steps in their process to 
use after a diagnosis of BPD had been assigned; the tool focuses on ruling in or ruling out 
the diagnosis.  Another difference is that the created clinical tool includes 
recommendations for laboratory and imaging studies.    
Algorta et al. (2013) completed a non-experimental, correlational study with a 
brief screening tool, the Family Index of Risk for Mood Issues (FIRM), to enhance the 
accuracy of pediatric BPD diagnoses.  This study and resulting tool is aligned with one of 
the steps that is proposed by Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012). 
It does not, however, give a comprehensive process for assessment, but provides a helpful 
tool for the clinician to use as a part of the process.  The sample included pediatric 
subjects aged 5-18 years (average 10.3 years), and their caregivers.  All subjects were 
seeking an outpatient psychiatric evaluation.   Subjects came from 273 families, from 
these families, 43 youth were found to be on the bipolar spectrum.  Caregivers completed 
the Mood Disorder Questionnaire – Parent (PMD-Q), and the FIRM appeared at the end 
of the PMD-Q.  Caregivers also completed a Child Behavior Checklist (CBCL) about the 
 7
youth subject.  Youth subjects were assessed with the Kiddie Schedule for Affective 
Disorders and Schizophrenia – present and lifetime (K-SADS-PL), supplemented with 
other interview questions.  Guardians were assessed for mental health history and were 
administered a Mini International Neuropsychiatric Interview (MINI).  Logistic 
regression was completed to determine if FIRM provided a significant improvement in 
the identification of BPD.  A t-test was also completed to establish if any test performed 
significantly better than another.  The FIRM was more sensitive to BPD than other tools 
and did not correlate to ADHD.  The logistic regression showed that FIRM provided a 
significant improvement in detecting BPD.  An identified strength of this study was that 
the subjects were all assessed in a thorough manner by highly trained research assistants.  
An identified limitation of the study was that the demographic characteristics of the 
study, with 90% of subjects being from low-income families, likely reduced the 
effectiveness of the FIRM.  This study is important to this project as it discussed the 
FIRM, which is an effective yet easily administered screening tool for the presence of 
BPD.  The FIRM is included in the resulting tool of this clinical project for its ease of use 
and effectiveness. 
Providing additional support to the previous two articles, Martelon, Wilens, 
Anderson, Morrison, and Wozniak (2012) completed a case-control family study to 
explore the link between challenges in the gestational and neonatal periods with the 
development of pediatric BPD.  Subjects were obtained from two other ongoing similarly 
designed studies.  There were 98 healthy controls, 120 bipolar patients, and 120 non-
affected siblings included.  Subjects under the age of 18 were assessed using the K-SADS 
– epidemiologic version (K-SADS-E), and those 18 and older were assessed with the 
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Structured Clinical Interview for DSM-IV (SCID).  Mothers of all subjects completed a 
module of the Diagnostic Interview for Children and Adolescents – Parent Version 
(DICA-P).  Statistical analyses included Chi square and t tests.  A significant relationship 
was found between BPD and neonatal challenges. No significant relationship was found 
between gestational challenges and the development of BPD.  One limitation of this study 
is the fact that the DICA-P was completed retrospectively, and there is a chance that 
mothers may not accurately remember the significance of any challenges with their 
pregnancy or the neonatal period.  This study is important to this project as it re-enforces 
the need to have a thorough gestational, neonatal, and pediatric history obtained during 
the clinical interview.  Both Algorta et al. (2013) and Youngstrom, Jenkins, Jensen-Doss, 
and Youngstrom (2012) discussed the importance of understanding family history as a 
part of the assessment process.   
Moving away from the process of assessment into the diagnosis itself, Hafeman et 
al. (2013) conducted a non-experimental, case-control study to determine if youth 
diagnosed with BPD, not otherwise specified (NOS) were similar to those with BPD I or 
BPD II.  The sample included 707 children with a mean age of 9.4 years, presenting for 
treatment at an identified outpatient clinic.  The subjects were evaluated and diagnosed 
with BPD I (n=71), BPD II (n=3), BPD NOS (n=88), or no BPD (n=545).  Subjects were 
assessed using the K-SADS-PL, young mania rating scale (YMRS), K-SADS Depression 
Rating Scale, K-SADS Mania Rating Scale (KMRS), and the Children's Global 
Assessment Scale (CGAS).  BPD II was eliminated from the analysis due to the low 
number of subjects with that diagnosis.  Analysis of variance (ANOVA) testing was 
completed for continuous variables, and Chi square testing for the categorical variables, 
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to determine differences between the three remaining groups.  BPD NOS showed no 
significant difference from BPD I in mood symptoms at baseline.  BPD NOS had lower 
KMRS than BPD I, but both had significantly elevated scores when compared to no BPD.  
CGAS also showed significant impairment in BPD NOS and BPD I compared to no 
BPD.  An identified strength of this study was the thorough diagnostic assessment given 
to the subjects, including a myriad of validated assessment tools.  This study is important 
to this project as it discussed the similarity in the clinical presentation for different 
diagnoses across the BPD spectrum.  
Providing a different perspective, Benti, Manicavasagar, Proudfoot, and Parker 
(2014) conducted a qualitative study with a phenomenological approach to understand 
the early experiences of patients with BPD, and how they differed from those diagnosed 
with unipolar depression (UD).  Some controversy still exists about diagnosing BPD in 
the pediatric population, and this study provided some information about individuals 
living with BPD.  There were 39 participants aged 18-35 years old; all were diagnosed 
before age 24.  Twenty participants had UD and 19 had BPD.  All participants were given 
the MINI, YMRS, and the Hamilton Rating Sale for Depression (HAM-D) by the same 
clinician to determine that they were in a state of euthymia at the time of the study.  After 
determining that they were eligible to participate based on diagnosis, age, and mood state, 
the participants completed a semi-structured interview.  Descriptive statistics were 
obtained for the demographic data of participants.  There was a trend noted for a younger 
age of onset in BPD than in UD.  Indicators for BPD that were revealed included: adverse 
home environments, more assertive and disinhibited personalities, and mood swings at a 
young age.  This study is important to the project as it gives insight to the age and nature 
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of the onset of symptoms.  This article provides support for the diagnosis and early 
treatment of BPD, based on the experiences of the subjects. 
Similar to Benti, Manicavasagar, Proudfoot, and Parker (2014), Carpenter-Song 
(2009) completed a qualitative study with an ethnographic focus, to learn about the lived 
experience of patients and families dealing with mental health issues.  One primary 
difference from the preceding article is that the previous study involved the patients 
recounting their earlier experiences, whereas Carpenter-Song studied pediatric patients 
and their families while they were still children. There were 20 families in the study: nine 
African American, ten Euro-American, and one Latino.  The socioeconomic statuses of 
the families ranged from upper middle class to low income.  Nineteen children in the 
study met criteria for BPD spectrum or ADHD.  Youth were evaluated using the K-
SADS-PL to determine their diagnosis for the study.  A semi-structured interview, the 
Subjective Experience of Illness and Medications in Youth was used to evaluate 
participants.  Interviews were conducted in participant homes over multiple sessions.  
The study included detailed descriptions of three families and provided some of their 
responses to questions about their lived experience. The medicalization of these 
conditions was discussed, along with the participant's experiences with providers.  An 
identified strength of this study is the ethnographic approach that is not taken into 
account in many quantitative studies.  It is possible that families, like the described 
African American families in this study, would not participate in some other quantitative 
research because they do not attribute these mental health concerns to individual 
pathology.  Having all perspectives considered and reported gives strength to this data 
and the study.  This study is useful for this project as it discussed the lived experience of 
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patients and families involved in the mental health system.  Additionally, it discussed 
important cultural considerations regarding attitudes about mental illness that are 
important to consider.  Families who do not believe in mental illness or sense stigma 
about seeking care might be less likely to seek help or discuss troubling symptoms. 
Neurobiological Changes 
 Chang et al. (2005) conducted a case-control study to examine structures of the 
limbic system in patients with BPD and healthy controls.  Twenty children and 
adolescents with BPD were recruited from an ongoing study.  Each of the subjects had a 
gender, age, and IQ-matched control recruited from the community.  SCID, K-SADS, 
and K-SADS-PL were used to evaluate subjects.  Bipolar patients were additionally 
evaluated with the YMRS.  T-tests were used to analyze the data obtained from magnetic 
resonance imaging (MRI) studies.  No statistical significance was seen between BPD 
subjects and controls for total brain volume, thalamus, caudate, and hippocampus.  Total 
amygdalar volume, as well as right and left amygdalar volume was significantly 
decreased in the BPD subjects.  Further study showed this reduction to be related to 
depletion of gray matter volume (GMV) in the right amygdala.  Treatment with lithium 
or valproic acid was shown to be somewhat protective of this change.  This study 
provides support for this project in that it demonstrates underlying neurobiological 
processes that appear to be a part of the BPD presentation.  It also supports that treatment 
of BPD can be protective against this neurobiological change; an important consideration 
when considering diagnosing BPD in the pediatric population. 
 Similar to Chang et al. (2005), Lisy et al. (2011) conducted a study that found 
changes in GMV in MRI scans of patients with BPD.  Additionally, both studies had 
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findings showing that treatment with certain medications for BPD is brain protective.  
Lisy et al. completed a longitudinal case-control study to assess changes in GMV in 
subjects with BPD and healthy controls.  Fifty-eight subjects with BPD and 48 healthy 
controls underwent a baseline MRI scan, and then a follow-up scan some months later 
(mean of 11months).  Assessments were completed using the K-SADS and the SCID 
based on the age of the subject.  BPD patients were in a variety of mood states at the time 
of their baseline MRI.  Healthy controls were found to have greater gray matter volume 
compared to BPD patients overall.  BPD patients, however, had increased gray matter 
volume over time.  There was a positive correlation in the bipolar group between the 
length of time between scans and the change in gray matter volume.  BPD patients 
receiving antipsychotics or anticonvulsants showed increases in the left frontal gyrus and 
the left medial gyrus, respectively.  This study did not note a change in GMV between 
scans in patients receiving lithium.  The longitudinal nature of this study is a strength.  
One limitation of this study is that subjects with nicotine dependence were not excluded 
from participation, and this has been linked to GMV changes in the past.  This study is 
important to the project as it demonstrated neurostructural changes related to BPD.  
Different from the preceding two studies, Xiao et al. (2013) conducted a case-
control study to determine neurologic changes of manic pediatric BPD patients.  Lisy et 
al. (2011) included patients in a variety of mood states, whereas Xiao et al. included only 
manic patients.  The study by Xiao et al. included 15 patients aged 12 to 17 years old 
from outpatient psychiatric clinics in China, and they were age and sex matched with 
healthy controls.  Subjects met criteria for BPD, had to have one previous manic or 
hypomanic episode, and were manic at the time of completing the study.  Participants 
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were evaluated using the K-SADS-PL, and the Wechsler Abbreviated Scale for 
intelligence.  BPD patients additionally completed the YMRS.  Statistical analysis was 
completed using Chi square tests and t tests.  MRI scans were completed, and changes 
were found in the bilateral hippocampus, right anterior cingulate cortex, right 
parahippocampal gyrus, and left caudate.  Chang et al. (2005) did not find changes in the 
caudate or hippocampal structures like this study did.  Some of this could be related to 
differences in study design.  This study demonstrated neurobiological changes that can be 
observed during the resting state, and during task completion in BPD.  This study is 
important to the project as it outlines some of the neurobiological changes that can be 
appreciated in the brain of the bipolar patient compared to a healthy control when there 
was no task being completed.  This information suggests that objective findings might be 
possible when diagnosing pediatric BPD. 
Exploring a different aspect of neurobiological function in BPD, Quiroz, Gray, 
Kato, and Manji (2008) completed a retrospective review to examine the role of 
mitochondrial function in BPD.  The authors noted evidence is emerging that 
mitochondria play a role in the ability for neurotransmitters to freely move between 
neurons.  Dysfunction in calcium transportation and utilization is another anomaly that 
has been documented in BPD; this could also be linked to mitochondrial function.  Over 
12,000 hippocampal genes from autopsied brains of patients with BPD, schizophrenia, 
and healthy controls were analyzed.  Forty-three genes were expressed in a diminished 
manner for BPD as opposed to schizophrenia.  Forty two percent of these changes were 
related to mitochondrial function.  It was noted that treatment with lithium and valproic 
acid were protective to brain function, similar to the other studies discussed that 
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completed MRI scans.  This article is important to the project as it explored the biologic 
basis for BPD.   
Susceptibility Genes and Genetic Linkage 
Lichtenstein et al. (2009) conducted a population-based retrospective study to 
assess heritability and environmental factors that contribute to susceptibility for 
schizophrenia, BPD, or a comorbidity of both conditions.  The sample was obtained by 
linking national registries.  Over nine million potential participants were identified, and 
the article stated that over 2 million families were analyzed.  Rates of disease in family 
members was compared to those with hospitalizations who were the same age and 
gender.  Different family types were analyzed in an attempt to separate genetic from 
environmental factors for susceptibility.  A generalized multivariate mixed linear model 
was used.  Heritability of schizophrenia was estimated to be 64%, and BPD was 
estimated to be 59%.  An identified limitation was that the data used to determine the 
sample was the lack of information about the diagnostic practices of the treating 
clinicians.  Additionally, they may not utilize a standardized approach to the assessment 
of BPD and did not know that their assigned diagnoses would be used for the purpose of 
this study.  This study supports this project as it demonstrated the high rate of heritability 
of BPD, warranting consideration of the genetic factors during the assessment of 
potential BPD cases. 
Different from Lichtenstein et al. (2009), Barden et al. (2006) completed a case-
control study to examine three different specific genes as potential factors leaving one 
susceptible to developing BPD.  The genes studied were: purinergic receptor P2X 7 
(P2RX7), purinergic receptor P2X 4 (P2RX4), and calcium/calmodulin dependent protein 
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kinase kinase 2 (CAMKK2).   Two hundred thirteen individuals from Quebec were 
identified using the French version of SCID.  There were 214 control subjects.  Blood 
samples were obtained from all subjects.  Fisher’s exact tests were used to analyze data.  
Single nucleotide polymorphism’s (SNP) associated with P2RX7 accounted for 56% of 
all SNP’s in this genetic area.  All three genes studied are implicated in the synaptic use 
of calcium and subsequent modulation of neurotransmitters.  The data obtained from this 
study suggest susceptibility to BPD may exist through P2RX7 and CAMKK2, though 
stronger in the former.  There was a significant association between 2 markers of P2RX7 
in BPD as compared to control subjects.  The authors also suggested that due to the space 
between implicated susceptibility genes, there may be a gene cluster associated with 
BPD.  This study is important to this project as it gives discussion to the biological basis 
of BPD, and offers some genetic markers that may be implicated in the development of 
BPD. 
 Doyle et al. (2010), explored genetic susceptibility to BPD, and like Barden et al. 
(2006), found some genes suggestive of playing a role in the development of the disorder.  
Doyle et al. additionally explored the heritability of BPD.  The authors completed a non-
experimental, correlational descriptive study to expand on previous research regarding 
the diagnosis and genetic basis of pediatric BPD.  Subjects were obtained from a group 
previously studied in a sibling-pair linkage ADHD project.  Subjects aged 6-17 years old 
were assessed using the K-SADS-E, and subjects 18 years old and older were assessed 
with the SCID.  Weschler Intelligence Scales (IQ) were completed for all subjects as 
well.  A CBCL was completed by guardians of subjects aged 6 to 18 years.  Genotyping 
was then completed on the subjects.  Youth with CBCL data were the focus on of the 
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main analysis.  The independent variable was the youth with the juvenile BPD phenotype 
based on the CBCL scores (CBCL-JBD).  Heritability for CBCL-JBD was found.  The 
genomic scans revealed suggestive linkage for youth with CBCL-JBD at 1p21.1 (changes 
with chromosome 1), 6p21.3 (changes with chromosome 6), and 8q21.13 (changes with 
chromosome 8), though no genetic markers had a statistically significant correlation to 
the phenotype.  An identified limitation of this study was that only 54% of CBCL were 
returned.  This study is important to the project because it discussed the heritability of 
BPD, and found some suggestive susceptibility genes, though statistical significance was 
not found.   
 Another exploration of genetic susceptibility for BPD was completed by Jang et 
al. (2015), who completed an animal study on transient receptor potential cation channel 
subfamily M member 2 (TRPM2) deficient mice, to explore the biologic basis of BPD in 
humans.  Many behavioral tasks were completed and video recorded.  Mice also 
underwent electroencephalogram studies and blood tests.  Animal handling protocols 
were followed, and this study was completed in Korea. One way ANOVA tests were used 
to analyze data obtained.  This study examined the changes associated with three 
mutations of TRPM2.  One particular mutation, D543E demonstrated significant changes 
in behavior and function.  Having these mutations leads to an inappropriate production of 
other proteins naturally occurring in the brain.  One of these, GSK-3, is known to be 
directly related to mood regulation.  The nature of this study being an animal study with 
interwoven knowledge of human BPD is both a strength and weakness.  The strength lies 
in the intricate and robust study that was completed, but the weakness is that this has not 
been replicated fully in the human population.  This study is important to this project by 
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providing information that could be directly related to the development of BPD in 
humans. 
 Olivera et al. (2014) explored the genetic factors related to BPD development 
from a different perspective.  The authors conducted a non-experimental, case-control 
study to determine if there was a genetic response to infection or inflammation that leaves 
one susceptible to the development of BPD.  DNA from 571 French patients with BPD 
(229 early onset before age 22, and 342 late onset), and 199 healthy controls were 
analyzed for toll-like receptor 2 (TLR2) polymorphisms.  All subjects were euthymic at 
the time of inclusion, as evidenced by completion of a Montgomery-Asberg Depression 
Rating Scale and a Mania Rating Scale.  The independent variable was the presence of 
BPD, and the dependent variables were the presence or absence of TLR2 polymorphisms.  
Genotype frequencies between the early onset, late onset, and healthy controls were 
performed using Chi square tests.  The TLR2 rs380499 TT and TLR2 rs4696480 TT 
genotypes were found to be significantly more present in early onset BPD patients than 
late onset.  No statistically significant difference was found between the late onset group 
and the healthy controls.  An identified strength of this study was the homogenous 
sample and a large number of sample subjects.  This study is relevant to the project as it 
provides information regarding background questions that should be asked during the 
clinical interview, and identified statistically significant susceptibility genes for pediatric 
BPD. 
 Deepening the body of evidence for genetic linkage, Shifman et al. (2004) 
conducted a case-control study to explore the association between catechol-O-
methyltransferase (COMT) and BPD.  This study was completed in Jerusalem, Israel.  
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There were 217 unrelated case subjects; diagnosis was confirmed with the SCID.  All 
subjects were of Ashkenazi Jewish descent.  Control samples were obtained from around 
1,050 healthy Ashkenazi individuals.  Chi square tests were completed to analyze data 
received.  Gender specific samples were run, as a gender effect had previously been 
identified with COMT.  A significant association was found between SNP’s of COMT 
and BPD.  Based on previous research, the data of this study also demonstrated a 
relationship between schizophrenia and BPD.  The size of the control group is a strength 
of this study. However, the study does not indicate if these controls were screened.  Some 
controls may have had BPD and did not know it.  Though the strength of the correlation 
between COMT and BPD has been found to be more modest in the decade since this 
research was completed, this article provides support for the completion of this project 
due to the relationship found with both BPD and schizophrenia. 
 Like other studies in this section, Zhou et al. (2009) completed a study to explore 
another potential gene leaving individuals susceptible to developing BPD.  Zhou et al. 
conducted a study that had a correlational component for European Caucasian families, 
and a case-control component for Chinese subjects.  The study was conducted to 
determine if there was a link between Sp4 transcription factor (Sp4) and BPD, as Sp4 is 
known to play a role in hippocampal development in animal studies.  Ten SNP’s located 
across Sp4 were evaluated.  RMANOVA tests were used to analyze the data obtained.  4 
SNP's were found to be statistically significant and associated with BPD.  The number of 
subjects and the fact that results were replicated in two different ethnic groups are 
strengths of this study.  The article is important for the project because it identifies a 
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susceptibility gene that was found to be statistically significant in a large sample across 
ethnic groups. 
Gaps in Research 
 Literature searches were completed in the CINAHL and PsycINFO databases 
using the search terms “assessment diagnosis pediatric bipolar disorder,” “assessment 
pediatric bipolar disorder,” and “pediatric bipolar disorder.”  Additionally, a search was 
completed in both CINAHL and PsycINFO for “susceptibility genes bipolar disorder,” as 
there is interest in incorporating emerging information regarding genetic polymorphisms 
that are related to BPD into this project.  Youngstrom, Birmaher, and Findling (2008) 
reviewed the sensitivity and specificity of symptoms to BPD and other conditions.  
Studies referenced in the literature review often utilized validated rating scales as a part 
of the assessment strategy.  This is helpful but does not seem substantial enough, as 
diagnostic challenges still exist.  Rucklidge (2008) found that retrospective completion of 
rating scale tools did not reveal prodromal periods for those patients who were diagnosed 
after puberty.  They did demonstrate symptoms that were indicative of psychopathology, 
however.  This re-enforces the need for thorough assessment during the childhood and 
adolescent years so that treatment onset is not delayed. Kessing, Vradi, and Andersen 
(2015) noted that of those diagnosed with pediatric BPD, 40.7% of patients received the 
diagnosis at their first point of contact, but 24% of these patients eventually were given a 
different diagnosis after follow up.   
 Faraone, Glatt, and Tsuang (2003) noted that pediatric BPD is often more severe, 
and may be under stronger genetic influence than adult onset BPD.  Several genes have 
been identified as leaving one susceptible to developing pediatric BPD.  One of these 
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genes was discussed in the article by Olivera et al. (2014) in the literature review above.  
Some of the others include specific polymorphisms of COMT, brain-derived 
neurotrophic factor (BDNF), and the dopamine transporter (DAT) (Mick et al., 2008).  
Many of these genetic pathways show susceptibility, but none of them provide a direct 
pathway to diagnosis based on the current information available.  Given the information 
available, and considering that no one tool provides a completely reliable pathway to 
diagnosis, this project is needed to provide as consistent and clear a path as possible to 
diagnosis. 
 
 
   
CHAPTER 3: METHODOLOGY 
Study Design and Research Questions 
 The project had several elements: a systematic review of the literature to inform 
practice, a survey of clinicians, and the development of a clinical tool that could be 
implemented to more thoroughly and consistently assess for pediatric BPD.  Research 
questions analyzed were: 
1) Is there a significant difference between the type of licensure that a clinician holds 
and the assessment strategies used in clinical practice? 
2) Is there a significant difference between the length of time a clinician has been in 
practice and the assessment strategies used in clinical practice? 
3) Is there a difference between the age ranges that clinicians treat and the 
assessment strategies used in clinical practice? 
Sampling and Method 
 Survey respondents were recruited via snowball sampling; approximately 50-100 
respondents were desired to minimize distribution errors in responses (Field, 2013).  
Criteria for inclusion required that the respondent be a medical doctor, physician’s 
assistant, nurse practitioner, or clinical nurse specialist working in the field of mental 
health.  Clinicians additionally needed to treat some children or adolescents in their 
practice to be included in the survey.  Children and adolescents, for this project, were 
defined as people aged 3 to 17 years.  Clinicians did not have to exclusively treat this age 
group and did not need to have any specific portion of their practice be dedicated to the 
child and adolescent population.  Exclusion criteria are any individuals who did not meet 
the aforementioned practice criteria.  All subjects were able to provide their informed 
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consent to participate in the survey, and none belonged to a protected category of 
subjects.  Several published studies explore aspects of the existence, assessment, and 
diagnosis of pediatric BPD, but there does not appear to be any published English 
literature other than Youngstrom, Jenkins, Jensen-Doss, and Youngstrom (2012) that 
address a process for assessment.  The similarities and differences between their article 
and this work were previously explored in this paper.  
 Respondent participation was voluntary.  The respondents received the link for 
the survey from people that they know, due to the snowball sampling methodology.  The 
potential respondent had the sole ability to click the link and begin the survey process.  
No investigational, experimental, or special procedures were used in the completion of 
the project.  Each respondent should have only completed the survey once, as addressed 
in the informed consent, and the location of completion was up to the respondent.  The 
survey could have been completed on any computer or mobile device that could access 
the survey website. 
Data Collection 
 The survey (Appendix B) was created via the Survey Monkey platform, and covered six 
areas: informed consent to participate, the age range treated by the clinician, the type of 
licensure of the clinician, the length of time the clinician had been in practice, what 
strategies they used to assess for pediatric BPD, and whether they felt a standardized 
assessment process would assist them in the assessment and diagnosis of pediatric BPD.  
Survey items contained primarily check box answers, and it was estimated that unless a 
clinician chose to write in free text, survey completion took about five to ten minutes.  
Institutional Review Board approval from California State University, Fresno was 
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obtained.  Data was collected from September 13, 2016, through October 12, 2016.  No 
standardized instruments were used for data collection in this project. 
Data Analysis 
Emphasis was placed on the descriptive statistics generated from the data 
received.  This provided information about current practice strategies employed by 
clinicians, which substantiated the need for the development of the clinical tool.  Three 
groupings of variables were subject to statistical analysis.   Chi square analysis was 
performed on: the age range treated by the clinician and what assessment strategies 
employed in practice, length of time in practice and assessment strategies employed in 
practice, and level of licensure and assessment strategies employed in practice (Field, 
2013a).  None of the Chi square analyses resulted in significant findings. However, the 
survey data yielded varied assessment and interview strategies (Appendix C). 
Potential Benefits 
 There were no immediate or direct benefits to any respondent who completed the 
survey.  Any respondent who wishes to receive results of the survey data was provided 
information to request this as a part of the informed consent.  It was anticipated that 
clinicians were likely to see more benefit from the resulting tool that was created, than 
from participation in the survey.  This tool will guide clinicians through a robust 
assessment of possible pediatric BPD, and aid them in more accurately diagnosing this 
condition.   
Potential Risks 
 Risks to respondents were minimal for this study.  Risks involved the time needed 
to complete the survey and any distress that occurred from examining their assessment 
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strategies.  There were no social, physical, economic, or legal risks anticipated for any 
survey respondent.  The clinical tool will be validated as a separate endeavor after 
completion of this project and academic program, so there was no risk at this time to any 
patient.  There were no violations of normal expectations. 
Precautions to Minimize Risk 
 Completion of the survey was voluntary and anonymous.  At no point during the 
survey was any personally identifying information gathered.  The respondents completed 
the survey in an electronic format.  There were no individual survey tools collected by 
any other means, and therefore no physical storage or destruction was necessary.  Survey 
data is accessed by the investigator on the survey website.  This website is username and 
password protected, preventing any unauthorized access to survey data.  Any physical 
data that is printed, and not maintained in an electronic form on the secured website, will 
be secured in a locked filing cabinet.  Data analysis reports from statistical software are 
being stored in a biometrically locked laptop computer.  
 
 
   
CHAPTER 4: RESULTS 
Data from the clinician survey was analyzed using IBM SPSS, version 23.  
Descriptive statistics, and frequencies were obtained in addition to completion of analysis 
related to the research questions.  Review of the literature yielded information related to 
the assessment of pediatric BPD, susceptibility genes related to BPD, and the 
neurobiological changes seen in BPD.  The information from the literature review, and 
data from the clinical survey were combined to guide the development of the clinical 
tool. 
Results 
 Sixteen respondents completed the required questions of the survey.  Twenty 
respondents began the survey; four either did not complete the required questions of the 
survey or did not meet inclusion criteria.  The sample was comprised of physicians (n=4, 
25%), nurse practitioners (n=11, 68.8%), and a clinical nurse specialist (n=1, 6.2%).  Half 
of these clinicians treated patients across the lifespan (n=8, 50%), while some treated 
child and adolescents only (n=6, 37.5%), and the remainder treated children, adolescents, 
and young adults (n=2, 12.5%).  The length of time these clinicians had been in practice 
was also explored.  The largest group of respondents had been in practice between six 
and ten years (n=7, 43.8%).  Other responses included: zero to five years (n=2, 12.5%), 
eleven to twenty years (n=3, 18.7%), and twenty-one or more years (n=4, 25%). 
Chi Square Analyses 
 Testing of the aforementioned research questions was completed by 
performing Chi square analyses to determine if there were any significant 
relationships between the assessment strategies used by clinicians and 1) the level 
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of licensure of the clinician (mood journaling p=0.055, sleep journaling p=0.113, 
rating scales p=0.379, lab studies p=0.195, will not diagnose p=0.660), 2) the 
length of time the clinician had been in practice (mood journaling p=0.454, sleep 
journaling p=0.917, rating scales p=0.450, lab studies p=0.468, will not diagnose 
p=0.558), and 3) the age range the clinician treated (mood journaling p=0.558, 
sleep journaling p=0.141, rating scales p=0.915, lab studies p=0.641, will not 
diagnose p=0.180).  None of the Chi square analyses resulted in significant 
findings.  None of the clinician respondents reported using imaging studies or 
genetic testing regularly, so there are no p values for these measures.  The 
weakness of the sample size may have contributed to the lack of significance in 
findings.  This should be considered, and more data obtained in the future.   
 
 
   
CHAPTER 5: DISCUSSION 
 
Discussion Regarding Assessment Strategies 
  Overall, clinicians demonstrated consistency in their responses regarding the 
symptoms assessed when diagnosing pediatric BPD.  Though no statistically significant 
findings were found between the assessment strategies used and the clinician survey data, 
there was variation seen in the responses to the assessment strategies employed in 
practice (see Appendix C, Chart 1).  The variation in responses is either random or 
related to a variable that was not studied.  It is presumed that use of the clinical tool will 
help to create greater consistency in the assessment strategies used.  The final question of 
the survey asked respondents whether or not a valid and reliable assessment tool would 
be helpful to them, the majority of respondents (n=14, 87.5%) indicated that this would 
be helpful to them.  Based on this data obtained from the clinician study, there should be 
openness to the diffusion of the tool and adoption of its process.  
 Data obtained regarding the family of origin showed some variation in responses 
as well (see Appendix C, Chart 2), though not as dramatically as the assessment 
strategies.  A thorough family history should be consistently obtained due to the 
heritability of BPD (Lichtenstein et al., 2009).  The significance of these particular 
aspects of family history are important in the assessment of pediatric BPD, further 
consistency in this area of assessment could yield more effective diagnostics.  Sleep 
disturbance is a common symptom of BPD.  Exploring patterns of this occurring in the 
family of origin can be helpful in identifying BPD in the patient; this response showed 
the greatest variation in responses in this section of questions. 
 28
 Clinicians were given the opportunity to provide free text responses regarding 
how they distinguish between the aforementioned conditions that have similar symptoms 
to pediatric BPD.  The common themes contained in the responses received for this 
question (n=10) included assessing for sleep disturbances, manic or grandiose periods, 
and thorough assessment.  One clinician responded that they would refer out any child or 
adolescent that they suspected had BPD.  Another free text question asked clinicians to 
explain their perspective if they would not diagnose BPD in a child or adolescent.  Two 
clinicians created responses for this question, and both indicated that the clinician would 
diagnose BPD in an adolescent if they met diagnostic criteria, but would not diagnose 
BPD in a child.  This question also did not require a response of the respondents. 
Project Outcomes 
 A clinical tool has been created (see Appendix D) to aid in the assessment and 
diagnosis of pediatric BPD.  This tool has been created by synthesizing the data obtained 
through the clinician survey, the information obtained during the literature review, and 
the clinical knowledge of the author.  The clinical tool is designed to be used in the 
mental health setting, and could also be used in the primary care setting as a means of 
determining when to refer for specialty assessment.   
The clinical tool provides a comprehensive checklist of symptoms and prompts 
the clinician to have the patient to mood journal.  After this, the tool guides the clinician 
to have the patient or their family to complete rating scales.  Though any reliable and 
validated screening tool is acceptable, information regarding the FIRM (Algorta et al., 
2013), and the Child Mania Rating Scale – Parent Version (CMRS-P) (Pavuluri, Henry, 
Devineni, Carbray, & Birmaher, 2006) are included.  Permission exists for the FIRM in 
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academic and research contexts.  The CMRS-P is available for download on the internet, 
and permission for use was separately obtained by the author (Appendix E).  If pediatric 
BPD is still suspected, further evaluation is recommended.  Laboratory studies are 
recommended to rule out any underlying medical comorbidities that may contribute to the 
clinical presentation; these would also allow for baseline levels to be obtained should 
pharmacologic management commence in the future.  Though the laboratory tests 
ordered should be based upon the assessment of the clinician, some routine 
recommendations to consider are: complete blood count with differential, comprehensive 
metabolic panel, lipid panel, glycosylated hemoglobin, and thyroid stimulating hormone.  
Other tests that may be warranted based on the individual patient presentation might 
include: urine drug screen, urine human chorionic gonadotropin, prolactin, and vitamin 
D.  Testing for methylenetetrahydrofolate reductase (MTHFR) polymorphisms should be 
considered on a case by case basis, as MTHFR polymorphisms are associated with mood 
struggles, although this is not diagnostic of BPD (Gilbody, Lewis, & Lightfoot, 2007).  It 
is possible that with this level of thorough assessment, BPD could be ruled in or out.  
However, if the clinical picture remains uncertain, MRI studies should be considered to 
assess for neurobiological changes.  Current research suggests that changes can be found 
in the scans of BPD patients; particular consistency has been noted in changes in GMV 
(James et al., 2011).   
Validation of this screening tool will be completed in the future.  After validity 
and reliability have been established, broader dissemination, publication, and training 
regarding the use of the tool will occur.  It is hoped that the use of this tool will provide a 
standardized platform for the assessment and diagnosis of BPD, and help to create greater 
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diagnostic accuracy.  It is anticipated that the tool will be available initially in pen and 
paper format, and eventually developed into a smartphone application.  Use of this tool 
will provide an innovative approach to assessment, that will enhance the efficiency and 
effectiveness of assessment.  These attributes of the tool will be addressed during training 
to aid in diffusion and adoption of the tool concepts. 
Limitations 
Crede (2010) reported the effects of random responding to the validity of 
psychological tests and in research.  The author noted that random responding could lead 
to erroneous correlational relationships being identified.  The converse could also be true, 
that relationships that would have appeared stronger had the responses not been random 
will not be identified.  It is unknown if the effects of random sampling contributed to the 
results of this project, further research is needed. 
A low response rate from clinicians was another limitation of this project.  
Cunningham, et al. (2015) noted that physicians are typically low responders to survey 
research.  The authors conducted survey research of various types of physicians to look at 
response rates.  Psychiatrists had by far the lowest return rate, and this was with a 
supported, advertised, and structured dissemination of the survey (Cunningham et al., 
2015).   
A perceived bias of this project could be that the clinician survey was 
disseminated to many professional contacts of the author.  However, these contacts 
allowed the survey to reach several large university medical centers, several university 
systems, the Ministry of Health in Singapore, several psychiatric hospitals, and a large 
medical group.  Additionally, a past president of the Northern California Regional 
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Organization of Child and Adolescent Psychiatry was able to disseminate the survey to 
clinician members.  Unfortunately, despite these seeming far-reaching contacts, very few 
surveys were completed.    
Recommendations for Further Study 
Mental health providers like psychologists, therapists, and social workers can 
diagnose pediatric BPD.  These clinicians cannot order imaging studies or laboratory 
studies, however, and as such, they were not included in this initial clinician survey.  
They should be included in any future clinician surveys to understand their assessment 
strategies, and to help garner more robust data.  Due to the low number of clinician 
respondents, continued study of clinician practices would be useful to see if any statistical 
significance could be obtained and to re-enforce the findings that were discovered. 
The most recent edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) brought updates to many pediatric mental health conditions.  The 
DSM-5 provides support for the diagnosis of pediatric BPD when the appropriate 
symptomatology exists (American Psychiatric Association, 2013).  One diagnostic 
addition to the DSM-5 was that of disruptive mood dysregulation disorder (DMDD) 
(American Psychiatric Association, 2013).  This diagnosis captures many of the children 
and adolescents that might have previously been mislabeled as having BPD.  This is 
considered a depressive disorder, however, not a cycling mood disorder like BPD.  
Irritability in children and adolescents is a hallmark feature of both conditions. However, 
a distinguishing factor is that the irritability in DMDD is persistently irritable, and in 
BPD there will be periods of irritability followed by other distinguishable mood states 
(American Psychiatric Association, 2013).  Stringaris et al. (2010) noted that youth with 
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severe mood dysregulation, as is seen in DMDD are very unlikely to develop a mixed or 
manic episode.  This type of episode would be seen relatively commonly in the BPD 
population.  Additionally, neurobiological differences can be appreciated in the brains of 
patients with severe mood dysregulation, like DMDD, as compared to those with BPD, 
when given the same tasks to complete (Adleman et al., 2011). 
Ensuring that the clinical tool is sensitive to BPD is important.  This will help 
reduce misdiagnosis of other similarly presenting conditions like DMDD, ODD, CD, and 
ADHD.  This consideration is one reason that the FIRM was selected as one of the 
recommended screening methods within the clinical tool.  Research has shown that the 
FIRM was more sensitive to BPD than other available scales, and was not sensitive to 
ADHD (Algorta et al., 2013).  The clinical tool now needs to be validated before 
disseminating it into clinical practice.  This is a crucial next research step to allow this 
project to proceed.  
Healthcare Improvement 
Creating consistency in the evaluation of pediatric BPD will help to ensure that 
the disorder is more accurately diagnosed.  A more robust evaluation process will likely 
help parents of potential BPD patients to be more accepting of the diagnosis, and thereby 
help ensure early treatment.  Early identification and treatment will help lead to more 
positive outcomes for this vulnerable population (Maniscalco & Hamrin, 2008).  The 
intent is for this clinical tool to reach beyond psychiatry, and into primary care as well.  
The assessment strategies will be clearly defined enough that those working in primary 
care would be comfortable completing the assessment, and referring for treatment if a 
diagnosis of BPD is likely.   
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Conclusion 
The development of the clinical tool provides a model for assessment that 
can be used to diagnose BPD in the pediatric population.  Data shows that the 
incidence of the pediatric BPD has been rising (Littrell & Lyons, 2010).  Current 
literature has demonstrated that there is evidence for biological and genetic 
changes that can be seen in the BPD patient, and the incorporation of the 
expanding field of science into diagnostic practices is warranted.  Clinician survey 
data demonstrated that while clinicians seem to be consistent in their assessment 
of symptoms of BPD, there is inconsistency in the use of other screening 
strategies.  Ultimately, the majority of clinician respondents indicated that a valid 
and reliable clinical tool would be helpful to them professionally.  This project 
seeks to provide such a tool, and it is hoped that broad diffusion and adoption of 
this tool will help to improve the care and outcomes of child and adolescent 
patients everywhere.
   
REFERENCES 
   
REFERENCES 
Adleman, N. E., Kayser, R., Dickstein, D., Blair, R. J., Pine, D., & Leibenluft, E. 
(2011). Neural correlates of reversal learning in severe mood dysregulation 
and pediatric bipolar disorder. Journal of the American Academy of Child & 
Adolescent Psychiatry, 50(11), 1173-1185.   
Algorta, G. P., Youngstrom, E. A., Phelps, J., Jenkins, M. M., Youngstrom, J. K., 
& Findling, R. L. (2013). An inexpensive family index of risk for mood 
issues improves identification of pediatric bipolar disorder. Psychological 
Assessment, 25(1), 12-22. doi:10.1037/a0029225  
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of 
Mental Disorders (5th ed.). Arlington, VA: American Psychiatric 
Association.   
Anderson, I. A., Haddad, P. M., & Scott, J. (2012). Bipolar disorder. British 
Medical Journal, 345(7889), 1-10. doi:10.1136/bmj.e8508  
Barden, N., Harvey, M., Gagne, B., Shink, E., Tremblay, M., Raymond, 
C.,...Muller-Myshok, B. (2006). Analysis of single nucleotide 
polymorphisms in genes in the chromosome 12Q24.31 region point to 
P2RX7 as a susceptibility gene to bipolar affective disorder. American 
Journal of Medical Genetics Part B, 141B, 374-382. 
doi:10.1002/ajmg.b.30303  
Benti, L., Manicavasagar, V., Proudfoot, J., & Parker, G. (2014). Identifying early 
indicators in bipolar disorder: A qualitative study. Psychiatric Quarterly, 85, 
143-153.   
36 
Carpenter-Song, E. (2009). Caught in the psychiatric net: Meanings and 
experiences of ADHD, pediatric bipolar disorder and mental health treatment 
among a diverse group of families in the United States. Culture, Medicine, 
and Psychiatry, 33, 61-85. doi:10.1007/s11013-008-9120-4  
Chang, K., Karchemskiy, A., Barnea-Goraly, N., Garrett, A., Simeonova, D. I., & 
Reiss, A. (2005). Reduced amygdalar gray matter volume in familial 
pediatric bipolar disorder. Journal of the American Academy of Child & 
Adolescent Psychiatry, 44(6), 565-573. 
doi:10.1097/01.chi.0000159948.75136.0d  
Crede, M. (2010). Random responding as a threat to the validity of effect sized 
estimates in correlational research. Educational and Psychological 
Measurement, 70(4), 596-612.   
Cunningham, C., Quan, H., Hemmelgarn, B., Noseworthy, T., Beck, C., & Dixon, 
E.,...Jette, N. (2015). Exploring physician specialist response rates to web-
based surveys. BMC Medical Research Methodology, 15(1), 32-39.   
Danner, S., Fristad, M. A., Arnold, L. E., Youngstrom, E. A., Birmaher, B., 
Horwitz, S. M.,...Kowatch, R. A. (2009). Early-onset bipolar spectrum 
disorders: Diagnostic issues. Clinical Child and Family Psychology Review, 
12, 271-293. doi:10.1007/s10567-009-0055-2  
Dearing, J. W. (2009). Applying diffusion of innovation theory to intervention 
development. Research on Social Work Practice, 19(5), 503-518.   
37 
DeHert, M., Correll, J. B., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, 
J.,...Leucht, S. (2011). Physical illness in patients with severe mental 
disorders. I. Prevalence, impact of medications and disparities in health care. 
World Psychiatry, 10, 52-77.   
Dilsaver, S. C. (2011). An estimate of the minimum economic burden of bipolar I 
and II disorders in the United States: 2009. Journal of Affective Disorders, 
129, 79-83. doi:10.1016/j.jad.2010.08.030  
Doyle, A. E., Biederman, J., Ferreira, M. A., Wong, P., Smoller, J  W., & Faraone, 
S. V. (2010). Suggestive linkage of the child behavior checklist juvenile 
bipolar disorder phenotype to 1p21, 6p21, and 8q21. Journal of the American 
Academy of Child & Adolescent Psychiatry, 49(4), 378-387. 
doi:10.1016/j.jac.2010.01.008  
Faraone, S. V., Glatt, S. J., & Tsuang, M. T. (2003). The genetics of pediatric-
onset bipolar disorder. Biological Psychiatry, 53, 970-977. 
doi:10.1016/S0006-3223(02)01893-0  
Field, A. (2013). Everything you never wanted to know about statistics. In 
Discovering statistics using IBM SPSS statistics (4th ed.pp. 40-88). Los 
Angeles, CA: Sage.   
Field, A. (2013a). Comparing several means: ANOVA (GLM 1). In Discovering 
statistics using IBM SPSS statistics (4th ed.pp. 429-477). Los Angeles, CA: 
Sage.   
38 
Gilbody, S., Lewis, S., & Lightfoot, T. (2007). Methylenetetrahydrofolate 
reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A 
HuGE review. American Journal of Epidemiology, 165(1), 1-13. 
doi:10.1093/aje/kwj347  
Goldstein, T. R. (2009). Suicidality in pediatric bipolar disorder. Child and 
Adolescent Psychiatric Clinics of North America, 18, 339-352. 
doi:10.1016/j.chc.2008.11.005  
Hafeman, D., Axelson, D., Demeter, C., Findling, R., Fristad, M. A., Kowatch, R. 
A.,...Birmaher, B. (2013). Phenomenology of bipolar disorder not otherwise 
specified in youth: A comparison of clinical characteristics across the 
spectrum of manic symptoms. Bipolar Disorders, 15, 240-252. 
doi:10.1111/bdi.1054  
James, A., Hough, M., James, S., Burge, L., Winmill, L., Nijhawan, S.,...Zarei, M. 
(2011). Structural brain and neuropsychometric changes associated with 
pediatric bipolar disorder with psychosis. Bipolar Disorders, 13, 16-27. 
doi:10.1111/j.1399-5618.2011.00891.x  
Jang, Y., Lee, S. H., Lee, B., Jung, S., Khalid, A., Uchida, K.,...Oh, U. (2015). 
TRPM2, a susceptibility gene for bipolar disorder, regulates glycogen 
synthase kinase-3 activity in the brain. The Journal of Neuroscience, 35(34), 
11811-11823. doi:10.1523/JNEUROSCI.5251-14.2015  
39 
Jenkins, M. M., Youngstrom, E. A., Youngstrom, J. K., Feeny, N. C., & Findling, 
R. L. (2011). Generalizability of evidence-based assessment 
recommendations for pediatric bipolar disorder. Psychological Assessment, 
24(2), 269-281. doi:10.1037/a0025775  
Kessing, L. V., Vradi, E., & Andersen, P. K. (2015). Diagnostic stability in 
pediatric bipolar disorder. Journal of Affective Disorders, 172, 417-421. 
doi:10.1016/j/jad.2014.10.037  
Lichtenstein, P., Yip, B. H., Bjork, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., 
& Hultman, C. M. (2009). Common genetic determinants of schizophrenia 
and bipolar disorder in Swedish families: A population based study. The 
Lancet, 373, 234-239.   
Lisy, M. E., Karvis, K. B., DelBello, M. P., Mills, N. P., Weber, W. A., Fleck, 
D.,...Adler, C. M. (2011). Progressive neurostructural changes in adolescent 
and adult patients with bipolar disorder. Bipolar Disorders, 13, 396-405. 
doi:10.1111/j.1399-5618.2011.00927  
Littrell, J., & Lyons, P. (2010). Pediatric bipolar disorder: Part I - is it related to 
classical bipolar. Children and Youth Services Review, 32, 945-964. 
doi:10.1016/j.childyouth.2010.03.020  
Maniscalco, E. R., & Hamrin, V. (2008). Assessment and diagnostic issues in 
pediatric bipolar disorder. Archives of Psychiatric Nursing, 22(6), 344-355. 
doi:10.1016/j.apnu.2007.08.006  
40 
Martelon, M. K., Wilens, T. E., Anderson, J. P., Morrison, N. R., & Wozniak, J. 
(2012). Are obstetrical, perinatal, and infantile difficulties associated with 
pediatric bipolar disorder? Bipolar Disorders, 14, 507-514. 
doi:10.1111/j.1399-5618.2012.01027.x  
Mick, E., Kim, J. W., Biederman, J., Wozniak, J., Wilens, T., Spencer, 
T.,...Faraone, S. V. (2008). Family based association study of pediatric 
bipolar disorder and the dopamine transporter gene (SLC6A3). American 
Journal of Medical Genetics Part B, 147B, 1182-1185. 
doi:10.1002/ajmg.b.30745  
Murray, C. E. (2009). Diffusion of innovation theory: A bridge for the research-
practice gap in counseling. Journal of Counseling & Development, 87, 108-
116.   
Olivera, J., Hamdani, N., Busson, M., Etain, B., Bennabi, M., Amokrane, 
J.,...Tamouza, R. (2014). Association between toll-like receptor 2 gene 
diversity and early-onset bipolar disorder. Journal of Affective Disorders, 
165, 135-141. doi:10.1016/j.jad.2014.04.059  
Pavuluri, M. N., Henry, D. B., Devineni, B., Carbray, J. A., & Birmaher, B. 
(2006). Child mania rating scale: Development, reliability, and validity. 
Journal of the American Academy of Child & Adolescent Psychiatry, 45(5), 
550-560.   
41 
Post, R. M., Altshuler, L., Leverich, G. S., Frye, M. A., Suppes, T., McElroy, S. 
L.,...Rowe, M. (2015). Relationship of clinical course of illness variables to 
medical comorbidities in 900 adult outpatients with bipolar disorder. 
Comprehensive Psychiatry, 56, 21-28. doi:10.1016/j.comppsych.2014.08.050  
Quiroz, J. A., Gray, N. A., Kato, T., & Manji, H. K. (2008). Mitochondrially 
mediated plasticity in the pathophysiology and treatment of bipolar disorder. 
Neuropsychopharmacology, 33, 2551-2565. doi:10.1038/sj.npp.1301671  
Rucklidge, J. J. (2008). Retrospective parent report of psychiatric histories: Do 
checklists reveal specific prodromal indicators for postpubertal-onset 
pediatric bipolar disorder? Bipolar Disorders, 10, 56-66.   
Shifman, S., Bronstein, M., Sternfeld, M., Pisante, A., Weizman, A., Reznik, 
I.,...Darvasi, A. (2004). COMT: A common susceptibility gene in bipolar 
disorder and schizophrenia. American Journal of Medical Genetics Part B, 
128B, 61-64. doi:10.1002/ajmg.b.30032 
Stringaris, A., Baroni, A., Haimm, C., Brotman, M., Lowe, C. H., Myers, 
F.,...Leibenluft, E. (2010). Pediatric bipolar disorder versus severe mood 
dysregulation: Risk for manic episodes on follow-up. Journal of the 
American Academy of Child & Adolescent Psychiatry, 49(4), 397-405.   
Weiss, R. B., Stange, J. P., Boland, E. M., Black, S. K., LaBelle, D. R., Abramson, 
L. Y., & Alloy, L. B. (2015). Kindling of life stress in bipolar disorder: 
Comparison of sensitization and autonomy models. Journal of Abnormal 
Psychiatry, 124(1), 4-16. doi:10.1037/abn0000014  
42 
Xiao, Q., Zhong, Y., Lu, D., Gao, W., Jiao, Q., Lu, G., & Su, L. (2013). Altered 
regional homogeneity in pediatric bipolar disorder during manic state: A 
resting-state fMRI study. PLoS One, 8(3), 1-9. 
doi:10.1371/journal.pone.0057978  
Youngstrom, E. A., Birmaher, B., & Findling, R. L. (2008). Pediatric bipolar 
disorder: Validity, phenomenology, and recommendations for diagnosis. 
Bipolar Disorders, 10, 194-214. doi:10.1111/j.1399-5618.2007.00563.x  
Youngstrom, E. A., Jenkins, M. M., Jensen-Doss, A., & Youngstrom, K. Y. 
(2012). Evidence-Based assessment strategies for pediatric bipolar disorder. 
The Israel Journal of Psychiatry and Related Sciences, 49(1), 15-27.   
Zhou, X., Tang, W., Greenwood, T. A., Guo, S., He, L., Geyer, M. A., & Kelsoe, 
J. R. (2009). Transcription factor SP4 is a susceptibility gene for bipolar 
disorder. PLoS One, 4(4), 1-11. doi:10.1371/journal.pone.0005196  
 
   
APPENDICES 
   
APPENDIX A: GLOSSARY OF TERMS 
 45 
Term Abbreviation 
Analysis of Variance ANOVA 
Attetion Deficit Hyperactivity Disorder ADHD 
Bipolar Disorder BPD 
Brain-derived Neurotrophic Factor BDNF 
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 CAMKK2 
Catechol-O-Methyltransferase COMT 
Child Behavior Checklist CBCL 
Child Mania Rating Scale – Parent Version CMRS-P 
Children’s Global Assessment Scale CGAS 
Conduct Disorder CD 
Diagnostic Interview for Children and Adolescents – Parent 
Version 
DICA-P 
Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition 
DSM-5 
Disruptive Mood Dysregulation Disorder DMDD 
Dopamine Transporter DAT 
Family Index of Risk for Mood Disorders FIRM 
 46 
Gray Matter Volume GMV 
Hamilton Rating Scale for Depression HAM-D 
Kiddie Schedule for Affective Disorders and Schizophrenia K-SADS 
Kiddie Schedule for Affective Disorders and Schizophrenia 
- Epidemiologic 
K-SADS-E 
Kiddie Schedule for Affective Disorders and Schizophrenia 
– Mania Rating Scale KMRS 
Kiddie Schedule for Affective Disorders and Schizophrenia 
– Present and Lifetime K-SADS-PL 
Magnetic Resonance Imaging MRI 
Methylenetetrahydrofolate Reductase MTHFR 
Mini International Neuropsychiatric Interview MINI 
Mood Disorder Questionnaire - Parent PMD-Q 
Oppositional Defiant Disorder ODD 
Purinergic Receptor P2X 4 P2RX4 
Purinergic Receptor P2X 7 P2RX7 
Single Nucleotide Polymorphism SNP 
Structured Clinical Interview for DSM-IV SCID 
Toll-like Receptor 2 TLR2 
 47 
Transient Receptor Potential Cation Channel Subfamily M 
Member 2 
TRPM2 
Unipolar Depression UD 
Young Mania Rating Scale YMRS 
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Appendix C – Clinician Data Charts 
Chart 1 – Assessment Strategies Employed 
 
Chart 2 – Family Screening 
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